<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01937832</url>
  </required_header>
  <id_info>
    <org_study_id>CTTQ04104-3-CTF</org_study_id>
    <nct_id>NCT01937832</nct_id>
  </id_info>
  <brief_title>A Phase III Study of Faropenem in the Treatment of Adult Community-acquired Bacterial Pneumonia</brief_title>
  <official_title>A Phase III Study to Evaluate the Efficacy and Safety of Faropenem in the Treatment of Adult Community-acquired Bacterial Pneumonia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Jiangsu Chia-tai Tianqing Pharmaceutical Co.,Ltd</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Jiangsu Chia-tai Tianqing Pharmaceutical Co.,Ltd</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the safety and Efficacy of Faropenem in
      community-acquired pneumonia (CAP) subjects
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Not yet recruiting</last_known_status>
  <start_date>October 2013</start_date>
  <primary_completion_date type="Anticipated">October 2015</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Per subject clinical cure rate</measure>
    <time_frame>7-14 days</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">540</enrollment>
  <condition>Community Acquired Pneumonia</condition>
  <arm_group>
    <arm_group_label>Ertapenem</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Faropenem</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Faropenem</intervention_name>
    <description>dosage form: Injection dosage:1200 mg frequency: Three times a day</description>
    <arm_group_label>Faropenem</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ertapenem</intervention_name>
    <description>dosage form: Injection dosage:1000 mg frequency: once a day</description>
    <arm_group_label>Ertapenem</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Patients aged between18~73 years, either male or female

          2. Patients requiring hospitalization or emergency room observation, and the need to
             receive intravenous antibiotic treatment

          3. Women of childbearing age having negative pregnancy test at the time of enrollment and
             agreeing to take effective contraceptive measures from the delivery to 7 ~14 days
             after stopping .(for example: oral contraception, injectable contraception, or implant
             contraception , spermicides and condoms, or IUDs).

          4. Comply with the following clinical, radiological and microbiological criteria of
             Community-Acquired Pneumonia(CAP)

          5. Patients had used ineffective systemic antimicrobial drugs before enrollment or had
             effective antimicrobial drugs within 72h before enrollment, used &lt;24h

          6. Informed consent granted

        Exclusion Criteria:

          1. Patients with atypical pneumonia infected by the Mycoplasma pneumoniae, Chlamydia
             pneumoniae, Legionella pneumophila bacteria;

          2. Patients infected by pathogens MRSA, Pseudomonas aeruginosa or Acinetobacter
             baumannii;

          3. Viral pneumonia;

          4. Aspiration pneumonia;

          5. Hospital-acquired pneumonia, including ventilator-associated pneumonia;

          6. Patients with Severe pneumonia who meet one primary criterion or three secondary
             criteria (See Appendix);

          7. Patients with a rapid progressive or end-stage disease, and can not survive until the
             end of the study period by antibiotic treatment;

          8. Patients with bronchial obstruction or a history of obstructive pneumonia (not
             including chronic obstructive pulmonary disease);

          9. Suffering from any of the following diseases: active tuberculosis, bronchiectasis,
             lung abscess, lung cancer, non-infectious interstitial lung disease, pulmonary edema,
             atelectasis, pulmonary embolism, pulmonary eosinophil infiltration disease and
             pulmonary vasculitis;

         10. Infections acquired from hospitals, nursing homes or other long-term care facilities,
             or patients hospitalized within 14 days prior to enrollment ;

         11. Allergic to penem and carbapenem antibiotic;

         12. Pregnancy or lactation in women;

         13. Patients with uncontrolled psychiatric history or those at risk of suicide two years
             prior to enrollment;

         14. A history of epilepsy or other central nervous system disorders in patients;

         15. Patients with Renal dysfunction, screening serum creatinine values above the upper
             limit of normal 10%;

         16. The Screening alanine aminotransferase (ALT) or aspartate aminotransferase (AST) is 3
             times the upper limit of the reference value, or total bilirubin beyond the upper
             limit of the normal range by 10% ;

         17. Serious diseases that affecting the immune system, such as: a human immunodeficiency
             virus (HIV) infection history, or CD4 + T-lymphocyte count &lt;200/200/mm3, or
             Neutrophilic granulocytopenia (neutrophil count &lt;1500/mm3), or hematologic
             malignancies or solid organ or splenectomy, etc;

         18. Patients who are taking steroid medications, at least 20mg daily dose of prednisone(or
             equivalent doses of other glucocorticoids);

         19. Patients who are accepting chemotherapy drug therapy or anti-cancer therapy, or plan
             to accept such treatment during the trial six months prior to enrollment;

         20. Alcohol or illicit drug abuse history;

         21. Patients who have accepted any other experimental drugs within 3 months prior to
             enrollment;

         22. more than 500ml blood donation within 3 months prior to enrollment;

         23. Patients who have participated in this clinical trial ever before;

         24. Combined use of other antibacterial drugs in patients;

         25. Patients are diagnosed to have potential increased risks, or there may be interference
             with clinical trials;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>73 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Wu Ju Fang</last_name>
    <phone>13816357099</phone>
    <email>Wujf53@gmail.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Anhui Provincial Hospital</name>
      <address>
        <city>Hefei</city>
        <state>Anhui</state>
        <zip>230001</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>The Third Affiliated Hospital of Sun Yat-sen University</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <zip>510630</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Taihe Hospital in Shiyan City</name>
      <address>
        <city>Shiyan</city>
        <state>Hubei</state>
        <zip>442000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>The Second Hospital of Jilin University</name>
      <address>
        <city>Changchun</city>
        <state>Jilin</state>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Qingdao Municipal Hospital</name>
      <address>
        <city>Qingdao</city>
        <state>Shandong</state>
        <zip>266000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Huashan Hospital ,Fudan University</name>
      <address>
        <city>Shanghai</city>
        <zip>200040</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Wu Ju fang</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The Second Hospital of Tianjin Medical University</name>
      <address>
        <city>Tianjin</city>
        <zip>300211</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>September 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 4, 2013</study_first_submitted>
  <study_first_submitted_qc>September 4, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 10, 2013</study_first_posted>
  <last_update_submitted>September 4, 2013</last_update_submitted>
  <last_update_submitted_qc>September 4, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 10, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pneumonia</mesh_term>
    <mesh_term>Pneumonia, Bacterial</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ertapenem</mesh_term>
    <mesh_term>beta-Lactams</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

